Skip to main content

ORIGINAL RESEARCH article

Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 15 - 2024 | doi: 10.3389/fmicb.2024.1451563

6-Gingerol and its derivatives inhibit Helicobacter pylori-induced gastric mucosal inflammation and improve gastrin and somatostatin secretion

Provisionally accepted
Jiali Qian Jiali Qian 1,2*ZHENNAN LI ZHENNAN LI 1,3Jinhui Wang Jinhui Wang 4*Yuxian Lin Yuxian Lin 1,5*Yingcong Yu Yingcong Yu 1,3,6*
  • 1 The Third Affiliated Hospital of Shanghai University, Wenzhou People’s Hospital, Wenzhou, Zhejiang Province, China
  • 2 Department of Nuclear Medicine, Sir Run Run Shaw Hospital, School of Medicine, Graduate School, Zhejiang University, Hangzhou, Jiangsu Province, China
  • 3 Shanghai University, Shanghai, China
  • 4 First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
  • 5 School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai University, Yantai, Shandong Province, China
  • 6 The Third Clinical Institute Affiliated To Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Helicobacter pylori (H.pylori) resistance has increased in recent years, and research and development of new drugs become a trend. In our study, three derivatives (JF-1, JF-2, JF-3) were synthesized using 6-gingerol as the main component, while JF-4, containing both 6-gingerol and 6-shogaol as the main components, was extracted from dried ginger. The MICs, determined by the ratio dilution method, were 80 µg/mL for JF-1, 40 µg/mL for JF-2, 30 µg/mL for JF-3, 40 µg/mL for JF-4, 60 µg/mL for 6-gingerol standard (SS), and 0.03 µg/mL for amoxicillin (AMX). After treating H. pylori-infected mice, the inflammation of the gastric mucosa was suppressed. The H. pylori eradication rate was 16.7% of JF-3 low-dose treatment (LDT), 25.0% of JF-3 high-dose treatment (HDT), 16.7% of JF-4 LDT, 16.7% of JF-4 HDT, 30% of SS LDT, 50% of SS HDT, and 36.4% of positive control group(PCG), respectively. The levels of gastrin, somatostatin, were significantly recovered in the JF-3 and JF-4 administration groups, and the effect was stronger in the high-dose group. These results demonstrated that 6-gingerol and its derivatives had significant anti-Helicobacter pylori effects and were promising potential treatments for H.pylori infection.

    Keywords: Helicobacter pylori, 6-gingerol, MIC, gastrin, Somatostatin, IFN-γ, IL-4, IL-8

    Received: 19 Jun 2024; Accepted: 17 Jul 2024.

    Copyright: © 2024 Qian, LI, Wang, Lin and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jiali Qian, The Third Affiliated Hospital of Shanghai University, Wenzhou People’s Hospital, Wenzhou, 325000, Zhejiang Province, China
    Jinhui Wang, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang Province, China
    Yuxian Lin, The Third Affiliated Hospital of Shanghai University, Wenzhou People’s Hospital, Wenzhou, 325000, Zhejiang Province, China
    Yingcong Yu, The Third Affiliated Hospital of Shanghai University, Wenzhou People’s Hospital, Wenzhou, 325000, Zhejiang Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.